Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Assisted Reproduction and Genetics
Published in: Journal of Assisted Reproduction and Genetics 7/2011

01-07-2011 | Gonadal Physiology and Disease

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study

Published in: Journal of Assisted Reproduction and Genetics | Issue 7/2011

Login to get access

Abstract

Purpose

Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome.

Methods

A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects’ ovulatory status was assessed after 3 months.

Results

There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH.

Conclusions

Both metformin and orlistat showed a similar effect on weight loss and ovulation rates.
Literature
1.
Adams H, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J. 1986;293:355–9.CrossRef
2.
Hull MG. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynaecol Endocrinol. 1987;1:235–45.CrossRef
3.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.PubMedCrossRef
4.
Strowitzki T, Capp E, von Eye Corleta H. The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients. Eur J Obstet Gynecol Reprod Biol. 2010;149:178–81.PubMedCrossRef
5.
Hahn S, Tan S, Elsenbruch S, Quadbeck B, Herrmann BL, Mann K, et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm Metab Res. 2005;37:438–44.PubMedCrossRef
6.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88.PubMedCrossRef
7.
Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, et al. Multi follicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone. Lancet. 1985;2:1375–9.PubMedCrossRef
8.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Exess Society guidline. J Clin Endocrinol Metab. 2006;91:4237–45.PubMedCrossRef
9.
Dunaif A, Segal K, Futterweit W, Dobrjanky A. Profound peripheral resistance independent of obesity in polycystic ovary syndrome. Diabetes. 1989;38:1165–74.PubMedCrossRef
10.
11.
Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–8.PubMedCrossRef
12.
Chang RJ. A practical approach to the diagnosis of polycysticovary syndrome. Am J Obstet Gynecol. 2004;191:713–7.PubMedCrossRef
13.
Richardson MR. Current perspectives in polycystic ovary syndrome. Am Fam Physician. 2003;68:697–704.PubMed
14.
Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83:2001–5.PubMedCrossRef
15.
Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O’Keefe M, Ghazzi MN. PCOS/Troglitazone Study Group. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003;79:932–7.PubMedCrossRef
16.
17.
18.
Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–8.PubMedCrossRef
19.
Carmina E, Lobo RA. Polycystic ovary syndrome: arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84:1897–9.PubMedCrossRef
20.
Kiddy DS, Hamilton-Fairley D, Bush A, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 1992;36:1105–11.CrossRef
21.
Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod. 1995;10:2705–12.PubMed
22.
Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;(3):CD003053.
23.
Dixon JB. Weight loss medications—where do they fit in? Aust Fam Physician. 2006;35:576–9.PubMed
24.
Padwal RS, Majumdar SR. Drug treatments for obesity: orlistst, sibutramine, and rimonabant. Lancet. 2007;369:71–7.PubMedCrossRef
25.
Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocinol (Oxf). 1999;51:231–6.CrossRef
26.
Hanjalic-beck A, Gabriel B, Schaefer W, Zahradnik HP, Schories M, Tempfer C. Metformin versus acarbose therapy in patients with polycystic ovary syndrome: a prospective randomized double—blind study. Gynecol Endocrinol. 2010;26:690–7.PubMedCrossRef
27.
Palomba S, Orio F, Falbo A, Manguso F, Russo T, Cascella T. Prospective parallel randomized, double—blind, double—dummy controlled clinical trial comparing clomiphene citrate and metformin as the first line treatment for ovulation induction in nonobese anovulatory women with poycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4068–74.PubMedCrossRef
28.
Palomba S, Orio F, Falbo A, Russo T, Tolino A. Clomiphene citrate versus metformin as first line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:3498–503.PubMedCrossRef
29.
Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2009;70:233–7.CrossRef
30.
Jayagopal V, Kilpatric ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:729–33.PubMedCrossRef
31.
Metwally M, Amer S, Li TC, Ledger WL. An RCT of metformin versus orlistat for the management of obese anovulatory women. Hum Reprod. 2009;24:966–75.PubMedCrossRef
32.
Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ. 2003;327:951–3.PubMedCrossRef
33.
De Sloover Koch Y, Ernst ME. Use of metformin in polycystic ovary syndrome. Ann Pharmacother. 2001;35:1644–7.PubMedCrossRef
34.
English PJ, Ashcroft A, Patterson M, Dovey TM, Halford JC, Harrison J, et al. Metformin Prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. Diab Metab Res Rev. 2007;23:299–303.CrossRef
35.
Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, et al. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J Pharmacol Exp Ther. 2004;310:614–9.PubMedCrossRef
36.
Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470–4.PubMedCrossRef
37.
Clark AM, Thirnley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998;13:1502–5.PubMedCrossRef
38.
Pasquali R, Antenucci D, Casmirri F, Venturoli S, Paradisi R, Fabbri Rm, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab. 1989;68:173–9.PubMedCrossRef
39.
Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath M, Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo—controlled, crossover trial. J Clin Endocrinol Metab. 2010;95:722–30.PubMedCrossRef
40.
Nestler JE, Jakubowics DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876–80.PubMedCrossRef
41.
Moghetti P, Castello R, Negri C, Tosi F, Perrone F. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized double-blind, placebo—controlled 6 month trial, followed by open long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139–46.PubMedCrossRef
42.
Velazquez EM, Mendoza S, Hamer T, Sosa F. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647–54.PubMedCrossRef
43.
Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double—blind, placebo—controlled trial. J Clin Endocrinol Metab. 2006;91:946–52.PubMedCrossRef
44.
Morin-papunem LC, Koivunem RM, Ruokonen A. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69:691–6.CrossRef
45.
Velazquez EM, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 1997;90:392–5.PubMedCrossRef
46.
Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jacubwicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002;77:209–15.PubMedCrossRef
47.
Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism. 1995;44:611–6.PubMedCrossRef
48.
Hamilton-Fairley D, Kiddy D, Anyaoku V, Koistinen R, Seppala M, Franks S. Response of sex hormone binding globulin and insulin- like growth factor binding protein −1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf). 1993;39:363–7.CrossRef
49.
Kiddy DS, Hamilton-Fairley D, Seppala M, Koistinen R, James VH, Reed MJ, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin- like growth factor. J Clin Endocrinol (Oxf). 1989;31:757–63.CrossRef
50.
Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LA. The insulin—related ovarian regulatory system in health and disease. Endocr Rev. 1999;20:535–82.PubMedCrossRef
51.
Soldani R, Cagnacci A, Yen SS. Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J Endocrinol. 1994;131:641–5.PubMedCrossRef
52.
Soldani R, Cagnacci A, Paoletti AM, Yen SS, Melis GB. Modulation of anterior pituitary luteinizing hormone response to gonadotropin-releasing hormone by insulin-like growth factor I in vitro. Fertil Steril. 1995;64:634–7.PubMed
Metadata
Title
The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study
Publication date
01-07-2011
Published in
Journal of Assisted Reproduction and Genetics / Issue 7/2011
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-011-9564-2

Other articles of this Issue 7/2011

Journal of Assisted Reproduction and Genetics 7/2011 Go to the issue

Genetics

Broadening our understanding by the use of molecular cytogenetic techniques: full monosomy 21

EDITOR'S COMMENTARY

NOBOX does right for the follicle reserve: insights into premature ovarian failure

Fertility Preservation

Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone

Assisted Reproduction Technologies

Embryo quality, blastocyst and ongoing pregnancy rates in oocyte donation patients whose embryos were monitored by time-lapse imaging

Genetics

Reliable preimplantation genetic diagnosis in thawed human embryos vitrified at cleavage stages without biopsy

Fertility Preservation

Effects of duration of cryo-storage of mouse oocytes on cryo-survival, fertilization and embryonic development following vitrification